Two genes, FOXM1 and CENPF, have been found to work together and drive the progression of the most lethal forms of prostate cancer. New research from the Herbert Irving Comprehensive Cancer Center at the Columbia University Medical Center suggests that neither gene alone significantly contributes to prostate cancer but when both genes are turned on, they work synergistically to activate pathways associated with the most aggressive form of the cancer.
